{"transactions":[{"id":4640514,"issuer":{"id":6428,"kind":"organization","name":"CODEXIS, INC.","symbol":"CDXS"},"owners":[{"id":64703,"kind":"person","name":"MOORE ALISON","position":1,"cik":"0001754937","reported_name":"MOORE ALISON","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-10-14T21:17:11.000Z","date":"2026-10-12","kind":"sale","planned":false,"acquired":false,"shares":6335,"price":1.3606,"value":8619.401,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of shares subject to Restricted Stock Units (\"RSUs\") of the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 119,582 restricted stock units."}],"balance_after":244171,"source":{"system":"sec-edgar","filing":"0001610717-26-000436","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754937/000161071726000436/form4.xml","form_type":"4"}},{"id":4616779,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":64703,"kind":"person","name":"MOORE ALISON","position":1,"cik":"0001754937","reported_name":"MOORE ALISON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2026-09-14T20:02:40.000Z","date":"2026-09-10","kind":"grant","planned":false,"acquired":true,"shares":16250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in full on the earlier of September 10, 2027, or the date of the Issuer's 2027 annual stockholder meeting."}],"balance_after":16250,"derivative":{"exercise_price":10.42,"expiration_date":"2036-09-09","underlying":"Common Stock","underlying_shares":16250},"source":{"system":"sec-edgar","filing":"0001193125-26-390524","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817241/000119312526390524/ownership.xml","form_type":"4"}},{"id":3573372,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":64703,"kind":"person","name":"MOORE ALISON","position":1,"cik":"0001754937","reported_name":"MOORE ALISON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2026-09-08T21:55:19.000Z","date":"2026-09-08","kind":"grant","planned":false,"acquired":true,"shares":13750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in full on the earlier of September 8, 2027, or the date of the Issuer's 2027 annual stockholder meeting."}],"balance_after":13750,"derivative":{"exercise_price":10.88,"expiration_date":"2036-09-07","underlying":"Common Stock","underlying_shares":13750},"source":{"system":"sec-edgar","filing":"0001193125-26-385409","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817241/000119312526385409/ownership.xml","form_type":"4"}},{"id":881690,"issuer":{"id":6428,"kind":"organization","name":"CODEXIS, INC.","symbol":"CDXS"},"owners":[{"id":64703,"kind":"person","name":"MOORE ALISON","position":1,"cik":"0001754937","reported_name":"MOORE ALISON","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-26T00:53:47.000Z","date":"2026-02-23","kind":"grant","planned":false,"acquired":true,"shares":993000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests and becomes exercisable with respect to 25% of the shares subject thereto on the first anniversary of the grant date, and with respect to 1/48th of the original number of shares subject thereto on each monthly anniversary thereafter, subject to the Reporting Person's continued employment through the applicable vesting dates."}],"balance_after":993000,"derivative":{"exercise_price":1.07,"expiration_date":"2036-02-23","underlying":"Common Stock","underlying_shares":993000},"source":{"system":"sec-edgar","filing":"0001610717-26-000072","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1200375/000161071726000072/form4.xml","form_type":"4"}},{"id":914230,"issuer":{"id":6428,"kind":"organization","name":"CODEXIS, INC.","symbol":"CDXS"},"owners":[{"id":64703,"kind":"person","name":"MOORE ALISON","position":1,"cik":"0001754937","reported_name":"MOORE ALISON","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-02-09T21:06:10.000Z","date":"2026-02-06","kind":"sale","planned":false,"acquired":false,"shares":3826,"price":1.3071,"value":5000.9646,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of shares subject to Restricted Stock Units (\"RSUs\") of the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 136,249 restricted stock units."}],"balance_after":250506,"source":{"system":"sec-edgar","filing":"0001610717-26-000045","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1200375/000161071726000045/form4.xml","form_type":"4"}},{"id":997616,"issuer":{"id":6428,"kind":"organization","name":"CODEXIS, INC.","symbol":"CDXS"},"owners":[{"id":64703,"kind":"person","name":"MOORE ALISON","position":1,"cik":"0001754937","reported_name":"MOORE ALISON","relationship":{"officer":true,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-11-17T22:11:27.000Z","date":"2025-11-13","kind":"grant","planned":false,"acquired":true,"shares":500000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option vests and becomes exercisable with respect to 25% of the shares subject thereto on the first anniversary of the grant date, and with respect to 1/48th of the original number of shares subject thereto on each monthly anniversary thereafter, subject to the Reporting Person's continued employment through the applicable vesting dates."}],"balance_after":500000,"derivative":{"exercise_price":1.63,"expiration_date":"2035-11-13","underlying":"Common Stock","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0001610717-25-000382","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1200375/000161071725000382/form4.xml","form_type":"4"}},{"id":997615,"issuer":{"id":6428,"kind":"organization","name":"CODEXIS, INC.","symbol":"CDXS"},"owners":[{"id":64703,"kind":"person","name":"MOORE ALISON","position":1,"cik":"0001754937","reported_name":"MOORE ALISON","relationship":{"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-11-17T22:11:27.000Z","date":"2025-11-13","kind":"grant","planned":false,"acquired":true,"shares":85000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These restricted stock units vest as to 1/3rd of the shares on each annual anniversary of the grant date, subject to the Reporting Person's continued employment through the applicable vesting dates."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 145,208 restricted stock units."}],"balance_after":254332,"source":{"system":"sec-edgar","filing":"0001610717-25-000382","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1200375/000161071725000382/form4.xml","form_type":"4"}},{"id":1018303,"issuer":{"id":6428,"kind":"organization","name":"CODEXIS, INC.","symbol":"CDXS"},"owners":[{"id":64703,"kind":"person","name":"MOORE ALISON","position":1,"cik":"0001754937","reported_name":"MOORE ALISON","relationship":{"officer":true,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2025-10-15T21:14:23.000Z","date":"2025-10-13","kind":"sale","planned":false,"acquired":false,"shares":6239,"price":2.5051,"value":15629.3189,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of shares subject to Restricted Stock Units (\"RSUs\") of the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 33,333 restricted stock units."}],"balance_after":169332,"source":{"system":"sec-edgar","filing":"0001610717-25-000363","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1200375/000161071725000363/form4.xml","form_type":"4"}},{"id":1101123,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":64703,"kind":"person","name":"MOORE ALISON","position":1,"cik":"0001754937","reported_name":"MOORE ALISON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2025-06-26T20:30:22.000Z","date":"2025-06-24","kind":"grant","planned":false,"acquired":true,"shares":13750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in full on the earlier of  June 24, 2026, or the date of the Issuer's 2026 annual stockholder meeting."}],"balance_after":13750,"derivative":{"exercise_price":1.61,"expiration_date":"2035-06-23","underlying":"Common Stock","underlying_shares":13750},"source":{"system":"sec-edgar","filing":"0001415889-25-018279","document":"form4-06262025_040610.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817241/000141588925018279/form4-06262025_040610.xml","form_type":"4"}},{"id":1278546,"issuer":{"id":6428,"kind":"organization","name":"CODEXIS, INC.","symbol":"CDXS"},"owners":[{"id":64703,"kind":"person","name":"MOORE ALISON","position":1,"cik":"0001754937","reported_name":"MOORE ALISON","relationship":{"officer":true,"officer_title":"Chief Technical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-08T01:18:24.000Z","date":"2025-02-05","kind":"grant","planned":false,"acquired":true,"shares":161250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests and becomes exercisable with respect to 25% of the shares subject thereto on the first anniversary of the grant date, and with respect to 1/48th of the original number of shares subject thereto on each monthly anniversary thereafter, subject to the Reporting Person's continued employment through the applicable vesting dates."}],"balance_after":161250,"derivative":{"exercise_price":4.37,"expiration_date":"2035-02-05","underlying":"Common Stock","underlying_shares":161250},"source":{"system":"sec-edgar","filing":"0000905148-25-000442","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1200375/000090514825000442/form4.xml","form_type":"4"}},{"id":1278545,"issuer":{"id":6428,"kind":"organization","name":"CODEXIS, INC.","symbol":"CDXS"},"owners":[{"id":64703,"kind":"person","name":"MOORE ALISON","position":1,"cik":"0001754937","reported_name":"MOORE ALISON","relationship":{"officer":true,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2025-02-08T01:18:24.000Z","date":"2025-02-05","kind":"grant","planned":false,"acquired":true,"shares":26875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These restricted stock units vest as to 1/3rd of the shares on each annual anniversary of the grant date, subject to the Reporting Person's continued employment through the applicable vesting dates."}],"balance_after":175571,"source":{"system":"sec-edgar","filing":"0000905148-25-000442","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1200375/000090514825000442/form4.xml","form_type":"4"}},{"id":1383006,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":64703,"kind":"person","name":"MOORE ALISON","position":1,"cik":"0001754937","reported_name":"MOORE ALISON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2024-10-23T00:18:32.000Z","date":"2024-10-21","kind":"grant","planned":false,"acquired":true,"shares":27500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-third of the shares vested following the grant date, with the remaining shares vesting monthly over an additional two years following October 21, 2024,"}],"balance_after":27500,"derivative":{"exercise_price":10.48,"expiration_date":"2034-10-20","underlying":"Common Stock","underlying_shares":27500},"source":{"system":"sec-edgar","filing":"0001415889-24-025537","document":"form4-10232024_121029.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817241/000141588924025537/form4-10232024_121029.xml","form_type":"4"}},{"id":1388048,"issuer":{"id":6428,"kind":"organization","name":"CODEXIS, INC.","symbol":"CDXS"},"owners":[{"id":64703,"kind":"person","name":"MOORE ALISON","position":1,"cik":"0001754937","reported_name":"MOORE ALISON","relationship":{"officer":true,"officer_title":"Chief Technical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-10-10T22:20:44.000Z","date":"2024-10-10","kind":"grant","planned":false,"acquired":true,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests and becomes exercisable with respect to 25% of the shares subject thereto on the first anniversary of September 30, 2024, and with respect to 1/48th of the original number of shares subject thereto on each monthly anniversary thereafter, subject to the Reporting Person's continued employment through the applicable vesting dates."}],"balance_after":300000,"derivative":{"exercise_price":2.97,"expiration_date":"2034-10-10","underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0000905148-24-002706","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1200375/000090514824002706/form4.xml","form_type":"4"}},{"id":1388047,"issuer":{"id":6428,"kind":"organization","name":"CODEXIS, INC.","symbol":"CDXS"},"owners":[{"id":64703,"kind":"person","name":"MOORE ALISON","position":1,"cik":"0001754937","reported_name":"MOORE ALISON","relationship":{"officer":true,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2024-10-10T22:20:44.000Z","date":"2024-10-10","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These restricted stock units vest as to 1/3rd of the shares on each annual anniversary of the grant date, subject to the Reporting Person's continued employment through the applicable vesting dates."}],"balance_after":148696,"source":{"system":"sec-edgar","filing":"0000905148-24-002706","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1200375/000090514824002706/form4.xml","form_type":"4"}},{"id":1480363,"issuer":{"id":6428,"kind":"organization","name":"CODEXIS, INC.","symbol":"CDXS"},"owners":[{"id":64703,"kind":"person","name":"MOORE ALISON","position":1,"cik":"0001754937","reported_name":"MOORE ALISON","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-06-13T22:27:03.000Z","date":"2024-06-11","kind":"grant","planned":false,"acquired":true,"shares":30120,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The restricted stock award vests as to all of the shares subject to the award on the earlier of the first anniversary of the date of grant or the next annual stockholder meeting, subject to the director's continued service to the Company on such vesting date."}],"balance_after":98696,"source":{"system":"sec-edgar","filing":"0000905148-24-001717","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1200375/000090514824001717/form4.xml","form_type":"4"}},{"id":1854060,"issuer":{"id":6428,"kind":"organization","name":"CODEXIS, INC.","symbol":"CDXS"},"owners":[{"id":64703,"kind":"person","name":"MOORE ALISON","position":1,"cik":"0001754937","reported_name":"MOORE ALISON","relationship":{"director":true}}],"security":"Common Stock","published_at":"2023-06-15T20:09:10.000Z","date":"2023-06-13","kind":"grant","planned":false,"acquired":true,"shares":34602,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The restricted stock award vests as to all of the shares subject to the award on the earlier of the first anniversary of the date of grant or the next annual stockholder meeting, subject to the director's continued service to the Company on such vesting date."}],"balance_after":68576,"source":{"system":"sec-edgar","filing":"0001610717-23-000160","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1200375/000161071723000160/form4.xml","form_type":"4"}},{"id":1938908,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":64703,"kind":"person","name":"MOORE ALISON","position":1,"cik":"0001754937","reported_name":"MOORE ALISON","relationship":{"officer":true,"officer_title":"Chief Technical Officer"}}],"security":"Stock Option (Right to buy)","published_at":"2023-03-25T00:19:18.000Z","date":"2023-03-22","kind":"grant","planned":false,"acquired":true,"shares":432738,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to the stock option shall vest on March 13, 2024, and the remaining shares shall vest in 36 equal monthly installments thereafter."}],"balance_after":432738,"derivative":{"exercise_price":5.04,"expiration_date":"2033-03-22","underlying":"Common Stock","underlying_shares":432738},"source":{"system":"sec-edgar","filing":"0001593968-23-000529","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1737287/000159396823000529/primary_01.xml","form_type":"4"}},{"id":1938907,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":64703,"kind":"person","name":"MOORE ALISON","position":1,"cik":"0001754937","reported_name":"MOORE ALISON","relationship":{"officer":true,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2023-03-25T00:19:18.000Z","date":"2023-03-22","kind":"grant","planned":false,"acquired":true,"shares":558094,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Includes 429,303 of performance RSUs which shall vest as follows: (1) 33% shall vest if the 30-day weighted average stock price is equal to or greater than $18 and (2) 67% shall vest upon the first regulatory approval of a product candidate. Notwithstanding the foregoing (1) any portion that vests upon the stock price threshold shall no longer vest and be terminated after three years from the grant date if such threshold has not been met in such three-year period, and (2) any portion that vests upon product candidate approval shall no longer vest and be terminated after five years from the grant date if such approval has not occurred in such five-year period."}],"balance_after":672731,"source":{"system":"sec-edgar","filing":"0001593968-23-000529","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1737287/000159396823000529/primary_01.xml","form_type":"4"}},{"id":1949517,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":64703,"kind":"person","name":"MOORE ALISON","position":1,"cik":"0001754937","reported_name":"MOORE ALISON","relationship":{"officer":true,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2023-03-16T20:49:16.000Z","date":"2023-03-14","kind":"tax_withholding","acquired":false,"shares":8351,"price":5.5071,"value":45989.7921,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.49 to $5.515, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 558 and 2000 share of the Issuer's common stock acquired by the reporting person on September 15, 2021 and on March 15, 2023 pursuant to an employee stock purchase program, respectively."}],"balance_after":114637,"source":{"system":"sec-edgar","filing":"0001593968-23-000492","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1737287/000159396823000492/primary_01.xml","form_type":"4"}},{"id":2229698,"issuer":{"id":6428,"kind":"organization","name":"CODEXIS, INC.","symbol":"CDXS"},"owners":[{"id":64703,"kind":"person","name":"MOORE ALISON","position":1,"cik":"0001754937","reported_name":"MOORE ALISON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-16T20:10:21.000Z","date":"2022-06-14","kind":"grant","acquired":true,"shares":11273,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The restricted stock award vests as to all of the shares subject to the award on the earlier of the first anniversary of the date of grant or the next annual stockholder meeting, subject to the director's continued service to the Company on such vesting date."}],"balance_after":33974,"source":{"system":"sec-edgar","filing":"0001567619-22-012970","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1200375/000156761922012970/doc1.xml","form_type":"4"}},{"id":2317434,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":64703,"kind":"person","name":"MOORE ALISON","position":1,"cik":"0001754937","reported_name":"MOORE ALISON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-03-25T21:51:18.000Z","date":"2022-03-23","kind":"grant","acquired":true,"shares":737179,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the stock option shall vest on March 13, 2023, and the remaining shares shall vest in 36 equal monthly installments thereafter."}],"balance_after":737179,"derivative":{"exercise_price":9.69,"expiration_date":"2032-03-23","underlying":"Common Stock","underlying_shares":737179},"source":{"system":"sec-edgar","filing":"0001214659-22-004373","document":"marketforms-55852.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1737287/000121465922004373/marketforms-55852.xml","form_type":"4"}},{"id":2326019,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":64703,"kind":"person","name":"MOORE ALISON","position":1,"cik":"0001754937","reported_name":"MOORE ALISON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2022-03-17T21:58:33.000Z","date":"2022-03-15","kind":"sale","acquired":false,"shares":8698,"price":7.6326,"value":66388.3548,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.58 to $7.73, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 1688 shares of the Issuer's common stock acquired by the reporting person on March 15, 2022 pursuant to an employee stock purchase program"}],"balance_after":120430,"source":{"system":"sec-edgar","filing":"0001214659-22-004083","document":"marketforms-55823.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1737287/000121465922004083/marketforms-55823.xml","form_type":"4"}},{"id":2663203,"issuer":{"id":6428,"kind":"organization","name":"CODEXIS, INC.","symbol":"CDXS"},"owners":[{"id":64703,"kind":"person","name":"MOORE ALISON","position":1,"cik":"0001754937","reported_name":"MOORE ALISON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-17T20:15:56.000Z","date":"2021-06-15","kind":"grant","acquired":true,"shares":4796,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The restricted stock award vests as to all of the shares subject to the award on the earlier of the first anniversary of the date of grant or the next annual stockholder meeting, subject to the director's continued service to the Company on such vesting date."}],"balance_after":22701,"source":{"system":"sec-edgar","filing":"0001567619-21-012318","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1200375/000156761921012318/doc1.xml","form_type":"4"}},{"id":2767495,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":64703,"kind":"person","name":"MOORE ALISON","position":1,"cik":"0001754937","reported_name":"MOORE ALISON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-03-30T20:53:37.000Z","date":"2021-03-26","kind":"grant","acquired":true,"shares":92365,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the stock option shall vest on March 13, 2022, and the remaining shares shall vest in 36 equal monthly installments thereafter."}],"balance_after":92365,"derivative":{"exercise_price":33.78,"expiration_date":"2031-03-26","underlying":"Common Stock","underlying_shares":92365},"source":{"system":"sec-edgar","filing":"0001214659-21-003605","document":"marketforms-52124.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1737287/000121465921003605/marketforms-52124.xml","form_type":"4"}},{"id":2767494,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":64703,"kind":"person","name":"MOORE ALISON","position":1,"cik":"0001754937","reported_name":"MOORE ALISON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2021-03-30T20:53:37.000Z","date":"2021-03-26","kind":"grant","acquired":true,"shares":24866,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":127440,"source":{"system":"sec-edgar","filing":"0001214659-21-003605","document":"marketforms-52124.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1737287/000121465921003605/marketforms-52124.xml","form_type":"4"}},{"id":2780729,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":64703,"kind":"person","name":"MOORE ALISON","position":1,"cik":"0001754937","reported_name":"MOORE ALISON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2021-03-17T21:00:40.000Z","date":"2021-03-15","kind":"sale","acquired":false,"shares":6164,"price":38.1391,"value":235089.4124,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.96 to $38.395, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 368 shares of the Issuer's common stock acquired by the reporting person on March 15, 2021 pursuant to an employee stock purchase program."}],"balance_after":102574,"source":{"system":"sec-edgar","filing":"0001214659-21-003239","document":"marketforms-51913.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1737287/000121465921003239/marketforms-51913.xml","form_type":"4"}},{"id":3007793,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":64703,"kind":"person","name":"MOORE ALISON","position":1,"cik":"0001754937","reported_name":"MOORE ALISON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-10-13T20:34:20.000Z","date":"2020-10-13","kind":"exercise","acquired":false,"shares":11031,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One-fourth of the 892,500 shares subject to the stock option vested on June 1, 2019, and the remaining shares vest in 36 successive equal monthly installments thereafter."}],"balance_after":579959,"derivative":{"exercise_price":2.27,"expiration_date":"2028-06-25","underlying":"Common Stock","underlying_shares":11031},"source":{"system":"sec-edgar","filing":"0001214659-20-008571","document":"marketforms-49856.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1737287/000121465920008571/marketforms-49856.xml","form_type":"4"}},{"id":3007792,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":64703,"kind":"person","name":"MOORE ALISON","position":1,"cik":"0001754937","reported_name":"MOORE ALISON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-10-13T20:34:20.000Z","date":"2020-10-12","kind":"exercise","acquired":false,"shares":24233,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One-fourth of the 892,500 shares subject to the stock option vested on June 1, 2019, and the remaining shares vest in 36 successive equal monthly installments thereafter."}],"balance_after":590990,"derivative":{"exercise_price":2.27,"expiration_date":"2028-06-25","underlying":"Common Stock","underlying_shares":24233},"source":{"system":"sec-edgar","filing":"0001214659-20-008571","document":"marketforms-49856.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1737287/000121465920008571/marketforms-49856.xml","form_type":"4"}},{"id":3007791,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":64703,"kind":"person","name":"MOORE ALISON","position":1,"cik":"0001754937","reported_name":"MOORE ALISON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2020-10-13T20:34:20.000Z","date":"2020-10-13","kind":"sale","acquired":false,"shares":11031,"price":42,"value":463302.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in June 2020."}],"balance_after":108370,"source":{"system":"sec-edgar","filing":"0001214659-20-008571","document":"marketforms-49856.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1737287/000121465920008571/marketforms-49856.xml","form_type":"4"}},{"id":3007790,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":64703,"kind":"person","name":"MOORE ALISON","position":1,"cik":"0001754937","reported_name":"MOORE ALISON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2020-10-13T20:34:20.000Z","date":"2020-10-13","kind":"exercise","acquired":true,"shares":11031,"price":2.27,"value":25040.37,"ownership":{"direct":true},"balance_after":119401,"source":{"system":"sec-edgar","filing":"0001214659-20-008571","document":"marketforms-49856.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1737287/000121465920008571/marketforms-49856.xml","form_type":"4"}},{"id":3007789,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":64703,"kind":"person","name":"MOORE ALISON","position":1,"cik":"0001754937","reported_name":"MOORE ALISON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2020-10-13T20:34:20.000Z","date":"2020-10-12","kind":"sale","acquired":false,"shares":24233,"price":42,"value":1017786.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in June 2020."}],"balance_after":108370,"source":{"system":"sec-edgar","filing":"0001214659-20-008571","document":"marketforms-49856.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1737287/000121465920008571/marketforms-49856.xml","form_type":"4"}},{"id":3007788,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":64703,"kind":"person","name":"MOORE ALISON","position":1,"cik":"0001754937","reported_name":"MOORE ALISON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2020-10-13T20:34:20.000Z","date":"2020-10-12","kind":"exercise","acquired":true,"shares":24233,"price":2.27,"value":55008.91,"ownership":{"direct":true},"balance_after":132603,"source":{"system":"sec-edgar","filing":"0001214659-20-008571","document":"marketforms-49856.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1737287/000121465920008571/marketforms-49856.xml","form_type":"4"}},{"id":3009143,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":64703,"kind":"person","name":"MOORE ALISON","position":1,"cik":"0001754937","reported_name":"MOORE ALISON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-10-09T21:49:00.000Z","date":"2020-10-09","kind":"exercise","acquired":false,"shares":30199,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One-fourth of the 892,500 shares subject to the stock option vested on June 1, 2019, and the remaining shares vest in 36 successive equal monthly installments thereafter."}],"balance_after":615223,"derivative":{"exercise_price":2.27,"expiration_date":"2028-06-25","underlying":"Common Stock","underlying_shares":30199},"source":{"system":"sec-edgar","filing":"0001214659-20-008532","document":"marketforms-49849.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1737287/000121465920008532/marketforms-49849.xml","form_type":"4"}},{"id":3009142,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":64703,"kind":"person","name":"MOORE ALISON","position":1,"cik":"0001754937","reported_name":"MOORE ALISON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-10-09T21:49:00.000Z","date":"2020-10-08","kind":"exercise","acquired":false,"shares":5065,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One-fourth of the 892,500 shares subject to the stock option vested on June 1, 2019, and the remaining shares vest in 36 successive equal monthly installments thereafter."}],"balance_after":645422,"derivative":{"exercise_price":2.27,"expiration_date":"2028-06-25","underlying":"Common Stock","underlying_shares":5065},"source":{"system":"sec-edgar","filing":"0001214659-20-008532","document":"marketforms-49849.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1737287/000121465920008532/marketforms-49849.xml","form_type":"4"}},{"id":3009141,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":64703,"kind":"person","name":"MOORE ALISON","position":1,"cik":"0001754937","reported_name":"MOORE ALISON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2020-10-09T21:49:00.000Z","date":"2020-10-09","kind":"sale","acquired":false,"shares":39509,"price":41,"value":1619869.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in June 2020."}],"balance_after":108370,"source":{"system":"sec-edgar","filing":"0001214659-20-008532","document":"marketforms-49849.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1737287/000121465920008532/marketforms-49849.xml","form_type":"4"}},{"id":3009140,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":64703,"kind":"person","name":"MOORE ALISON","position":1,"cik":"0001754937","reported_name":"MOORE ALISON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2020-10-09T21:49:00.000Z","date":"2020-10-09","kind":"exercise","acquired":true,"shares":30199,"price":2.27,"value":68551.73,"ownership":{"direct":true},"balance_after":147879,"source":{"system":"sec-edgar","filing":"0001214659-20-008532","document":"marketforms-49849.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1737287/000121465920008532/marketforms-49849.xml","form_type":"4"}},{"id":3009139,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":64703,"kind":"person","name":"MOORE ALISON","position":1,"cik":"0001754937","reported_name":"MOORE ALISON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2020-10-09T21:49:00.000Z","date":"2020-10-08","kind":"sale","acquired":false,"shares":5065,"price":41,"value":207665.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in June 2020."}],"balance_after":117680,"source":{"system":"sec-edgar","filing":"0001214659-20-008532","document":"marketforms-49849.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1737287/000121465920008532/marketforms-49849.xml","form_type":"4"}},{"id":3009138,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":64703,"kind":"person","name":"MOORE ALISON","position":1,"cik":"0001754937","reported_name":"MOORE ALISON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2020-10-09T21:49:00.000Z","date":"2020-10-08","kind":"exercise","acquired":true,"shares":5065,"price":2.27,"value":11497.55,"ownership":{"direct":true},"balance_after":122745,"source":{"system":"sec-edgar","filing":"0001214659-20-008532","document":"marketforms-49849.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1737287/000121465920008532/marketforms-49849.xml","form_type":"4"}},{"id":3009781,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":64703,"kind":"person","name":"MOORE ALISON","position":1,"cik":"0001754937","reported_name":"MOORE ALISON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-10-08T21:03:57.000Z","date":"2020-10-06","kind":"exercise","acquired":false,"shares":35264,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"One-fourth of the 892,500 shares subject to the stock option vested on June 1, 2019, and the remaining shares vest in 36 successive equal monthly installments thereafter."}],"balance_after":650487,"derivative":{"exercise_price":2.27,"expiration_date":"2028-06-25","underlying":"Common Stock","underlying_shares":35264},"source":{"system":"sec-edgar","filing":"0001214659-20-008506","document":"marketforms-49846.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1737287/000121465920008506/marketforms-49846.xml","form_type":"4"}},{"id":3009780,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":64703,"kind":"person","name":"MOORE ALISON","position":1,"cik":"0001754937","reported_name":"MOORE ALISON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2020-10-08T21:03:57.000Z","date":"2020-10-06","kind":"sale","acquired":false,"shares":44574,"price":40,"value":1782960.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in June 2020."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 718 shares of the Issuer's common stock acquired by the reporting person on September 15, 2020 pursuant to an employee stock purchase program."}],"balance_after":117680,"source":{"system":"sec-edgar","filing":"0001214659-20-008506","document":"marketforms-49846.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1737287/000121465920008506/marketforms-49846.xml","form_type":"4"}},{"id":3009779,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":64703,"kind":"person","name":"MOORE ALISON","position":1,"cik":"0001754937","reported_name":"MOORE ALISON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2020-10-08T21:03:57.000Z","date":"2020-10-06","kind":"exercise","acquired":true,"shares":35264,"price":2.27,"value":80049.28,"ownership":{"direct":true},"balance_after":161536,"source":{"system":"sec-edgar","filing":"0001214659-20-008506","document":"marketforms-49846.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1737287/000121465920008506/marketforms-49846.xml","form_type":"4"}},{"id":3056893,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":64703,"kind":"person","name":"MOORE ALISON","position":1,"cik":"0001754937","reported_name":"MOORE ALISON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-08-14T20:04:39.000Z","date":"2020-08-13","kind":"exercise","acquired":false,"shares":32451,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-fourth of the 892,500 shares subject to the stock option vested on June 1, 2019, and the remaining shares vest in 36 successive equal monthly installments thereafter."}],"balance_after":685751,"derivative":{"exercise_price":2.27,"expiration_date":"2028-06-25","underlying":"Common Stock","underlying_shares":32451},"source":{"system":"sec-edgar","filing":"0001214659-20-007184","document":"marketforms-49454.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1737287/000121465920007184/marketforms-49454.xml","form_type":"4"}},{"id":3056892,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":64703,"kind":"person","name":"MOORE ALISON","position":1,"cik":"0001754937","reported_name":"MOORE ALISON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2020-08-14T20:04:39.000Z","date":"2020-08-13","kind":"exercise","acquired":true,"shares":32451,"price":2.27,"value":73663.77,"ownership":{"direct":true},"balance_after":126272,"source":{"system":"sec-edgar","filing":"0001214659-20-007184","document":"marketforms-49454.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1737287/000121465920007184/marketforms-49454.xml","form_type":"4"}},{"id":3105201,"issuer":{"id":6428,"kind":"organization","name":"CODEXIS, INC.","symbol":"CDXS"},"owners":[{"id":64703,"kind":"person","name":"MOORE ALISON","position":1,"cik":"0001754937","reported_name":"MOORE ALISON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-06-18T20:10:38.000Z","date":"2020-06-16","kind":"grant","acquired":true,"shares":17905,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Restricted stock. The restricted stock vests as to 1/3 of the shares on June 16, 2021, another 1/3 of the shares on June 16, 2022 and the final 1/3 of the shares on June 16, 2023."}],"balance_after":17905,"source":{"system":"sec-edgar","filing":"0001567619-20-012366","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1200375/000156761920012366/doc1.xml","form_type":"4"}},{"id":3198879,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":64703,"kind":"person","name":"MOORE ALISON","position":1,"cik":"0001754937","reported_name":"MOORE ALISON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-03-20T20:37:37.000Z","date":"2020-03-18","kind":"grant","acquired":true,"shares":109600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the stock option shall vest on March 13, 2021, and the remaining shares shall vest in 36 equal monthly installments thereafter."}],"balance_after":109600,"derivative":{"exercise_price":18.22,"expiration_date":"2030-03-17","underlying":"Common Stock","underlying_shares":109600},"source":{"system":"sec-edgar","filing":"0001214659-20-002805","document":"marketforms-48391.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1737287/000121465920002805/marketforms-48391.xml","form_type":"4"}},{"id":3198878,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":64703,"kind":"person","name":"MOORE ALISON","position":1,"cik":"0001754937","reported_name":"MOORE ALISON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2020-03-20T20:37:37.000Z","date":"2020-03-18","kind":"grant","acquired":true,"shares":30800,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":93821,"source":{"system":"sec-edgar","filing":"0001214659-20-002805","document":"marketforms-48391.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1737287/000121465920002805/marketforms-48391.xml","form_type":"4"}},{"id":3201677,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":64703,"kind":"person","name":"MOORE ALISON","position":1,"cik":"0001754937","reported_name":"MOORE ALISON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2020-03-18T20:32:47.000Z","date":"2020-03-16","kind":"sale","acquired":false,"shares":3750,"price":19.1947,"value":71980.125,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units.  This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.02 to $19.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Includes 704 shares of the Issuer's common stock acquired by the reporting person on March 16, 2020 pursuant to an employee stock purchase program."}],"balance_after":63021,"source":{"system":"sec-edgar","filing":"0001214659-20-002736","document":"marketforms-48347.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1737287/000121465920002736/marketforms-48347.xml","form_type":"4"}},{"id":3410450,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":64703,"kind":"person","name":"MOORE ALISON","position":1,"cik":"0001754937","reported_name":"MOORE ALISON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-09-18T23:05:30.000Z","date":"2019-09-18","kind":"exercise","acquired":false,"shares":21067,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"One-fourth of the 892,500 shares subject to the stock option vested on June 1, 2019, and the remaining shares vest in 36 successive equal monthly installments thereafter."}],"balance_after":718202,"derivative":{"exercise_price":2.27,"expiration_date":"2028-06-25","underlying":"Common Stock","underlying_shares":21067},"source":{"system":"sec-edgar","filing":"0001214659-19-005941","document":"marketforms-45786.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1737287/000121465919005941/marketforms-45786.xml","form_type":"4"}},{"id":3410449,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":64703,"kind":"person","name":"MOORE ALISON","position":1,"cik":"0001754937","reported_name":"MOORE ALISON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-09-18T23:05:30.000Z","date":"2019-09-17","kind":"exercise","acquired":false,"shares":22503,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"One-fourth of the 892,500 shares subject to the stock option vested on June 1, 2019, and the remaining shares vest in 36 successive equal monthly installments thereafter."}],"balance_after":739269,"derivative":{"exercise_price":2.27,"expiration_date":"2028-06-25","underlying":"Common Stock","underlying_shares":22503},"source":{"system":"sec-edgar","filing":"0001214659-19-005941","document":"marketforms-45786.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1737287/000121465919005941/marketforms-45786.xml","form_type":"4"}},{"id":3410448,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":64703,"kind":"person","name":"MOORE ALISON","position":1,"cik":"0001754937","reported_name":"MOORE ALISON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-09-18T23:05:30.000Z","date":"2019-09-16","kind":"exercise","acquired":false,"shares":5257,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"One-fourth of the 892,500 shares subject to the stock option vested on June 1, 2019, and the remaining shares vest in 36 successive equal monthly installments thereafter."}],"balance_after":761772,"derivative":{"exercise_price":2.27,"expiration_date":"2028-06-25","underlying":"Common Stock","underlying_shares":5257},"source":{"system":"sec-edgar","filing":"0001214659-19-005941","document":"marketforms-45786.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1737287/000121465919005941/marketforms-45786.xml","form_type":"4"}},{"id":3410447,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":64703,"kind":"person","name":"MOORE ALISON","position":1,"cik":"0001754937","reported_name":"MOORE ALISON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2019-09-18T23:05:30.000Z","date":"2019-09-18","kind":"sale","acquired":false,"shares":21067,"price":32.1295,"value":676872.1765,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.00 to $32.29, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":66067,"source":{"system":"sec-edgar","filing":"0001214659-19-005941","document":"marketforms-45786.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1737287/000121465919005941/marketforms-45786.xml","form_type":"4"}},{"id":3410446,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":64703,"kind":"person","name":"MOORE ALISON","position":1,"cik":"0001754937","reported_name":"MOORE ALISON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2019-09-18T23:05:30.000Z","date":"2019-09-18","kind":"exercise","acquired":true,"shares":21067,"price":2.27,"value":47822.09,"ownership":{"direct":true},"balance_after":87134,"source":{"system":"sec-edgar","filing":"0001214659-19-005941","document":"marketforms-45786.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1737287/000121465919005941/marketforms-45786.xml","form_type":"4"}},{"id":3410445,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":64703,"kind":"person","name":"MOORE ALISON","position":1,"cik":"0001754937","reported_name":"MOORE ALISON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2019-09-18T23:05:30.000Z","date":"2019-09-17","kind":"sale","acquired":false,"shares":22503,"price":32.1095,"value":722560.0785,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.00 to $32.42, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":66067,"source":{"system":"sec-edgar","filing":"0001214659-19-005941","document":"marketforms-45786.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1737287/000121465919005941/marketforms-45786.xml","form_type":"4"}},{"id":3410444,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":64703,"kind":"person","name":"MOORE ALISON","position":1,"cik":"0001754937","reported_name":"MOORE ALISON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2019-09-18T23:05:30.000Z","date":"2019-09-17","kind":"exercise","acquired":true,"shares":22503,"price":2.27,"value":51081.81,"ownership":{"direct":true},"balance_after":88570,"source":{"system":"sec-edgar","filing":"0001214659-19-005941","document":"marketforms-45786.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1737287/000121465919005941/marketforms-45786.xml","form_type":"4"}},{"id":3410443,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":64703,"kind":"person","name":"MOORE ALISON","position":1,"cik":"0001754937","reported_name":"MOORE ALISON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2019-09-18T23:05:30.000Z","date":"2019-09-16","kind":"sale","acquired":false,"shares":5257,"price":32.0019,"value":168233.9883,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.00 to $32.03, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":66067,"source":{"system":"sec-edgar","filing":"0001214659-19-005941","document":"marketforms-45786.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1737287/000121465919005941/marketforms-45786.xml","form_type":"4"}},{"id":3410442,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":64703,"kind":"person","name":"MOORE ALISON","position":1,"cik":"0001754937","reported_name":"MOORE ALISON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2019-09-18T23:05:30.000Z","date":"2019-09-16","kind":"exercise","acquired":true,"shares":5257,"price":2.27,"value":11933.39,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 694 shares of the Issuer's common stock acquired by the reporting person on September 13, 2019 pursuant to an employee stock purchase program."}],"balance_after":71324,"source":{"system":"sec-edgar","filing":"0001214659-19-005941","document":"marketforms-45786.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1737287/000121465919005941/marketforms-45786.xml","form_type":"4"}},{"id":3452952,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":64703,"kind":"person","name":"MOORE ALISON","position":1,"cik":"0001754937","reported_name":"MOORE ALISON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-07-30T22:23:39.000Z","date":"2019-07-30","kind":"exercise","acquired":false,"shares":11819,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"One-fourth of the 892,500 shares subject to the stock option vested on June 1, 2019, and the remaining shares vest in 36 successive equal monthly installments thereafter."}],"balance_after":767029,"derivative":{"exercise_price":2.27,"expiration_date":"2028-06-25","underlying":"Common Stock","underlying_shares":11819},"source":{"system":"sec-edgar","filing":"0001209191-19-043755","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1737287/000120919119043755/doc4.xml","form_type":"4"}},{"id":3452951,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":64703,"kind":"person","name":"MOORE ALISON","position":1,"cik":"0001754937","reported_name":"MOORE ALISON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-07-30T22:23:39.000Z","date":"2019-07-29","kind":"exercise","acquired":false,"shares":23815,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"One-fourth of the 892,500 shares subject to the stock option vested on June 1, 2019, and the remaining shares vest in 36 successive equal monthly installments thereafter."}],"balance_after":778848,"derivative":{"exercise_price":2.27,"expiration_date":"2028-06-25","underlying":"Common Stock","underlying_shares":23815},"source":{"system":"sec-edgar","filing":"0001209191-19-043755","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1737287/000120919119043755/doc4.xml","form_type":"4"}},{"id":3452950,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":64703,"kind":"person","name":"MOORE ALISON","position":1,"cik":"0001754937","reported_name":"MOORE ALISON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-07-30T22:23:39.000Z","date":"2019-07-26","kind":"exercise","acquired":false,"shares":13193,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"One-fourth of the 892,500 shares subject to the stock option vested on June 1, 2019, and the remaining shares vest in 36 successive equal monthly installments thereafter."}],"balance_after":802663,"derivative":{"exercise_price":2.27,"expiration_date":"2028-06-25","underlying":"Common Stock","underlying_shares":13193},"source":{"system":"sec-edgar","filing":"0001209191-19-043755","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1737287/000120919119043755/doc4.xml","form_type":"4"}},{"id":3452949,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":64703,"kind":"person","name":"MOORE ALISON","position":1,"cik":"0001754937","reported_name":"MOORE ALISON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2019-07-30T22:23:39.000Z","date":"2019-07-30","kind":"sale","acquired":false,"shares":11819,"price":29.845,"value":352738.055,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.36 to $30.16, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":65373,"source":{"system":"sec-edgar","filing":"0001209191-19-043755","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1737287/000120919119043755/doc4.xml","form_type":"4"}},{"id":3452948,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":64703,"kind":"person","name":"MOORE ALISON","position":1,"cik":"0001754937","reported_name":"MOORE ALISON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2019-07-30T22:23:39.000Z","date":"2019-07-30","kind":"exercise","acquired":true,"shares":11819,"price":2.27,"value":26829.13,"ownership":{"direct":true},"balance_after":77192,"source":{"system":"sec-edgar","filing":"0001209191-19-043755","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1737287/000120919119043755/doc4.xml","form_type":"4"}},{"id":3452947,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":64703,"kind":"person","name":"MOORE ALISON","position":1,"cik":"0001754937","reported_name":"MOORE ALISON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2019-07-30T22:23:39.000Z","date":"2019-07-29","kind":"sale","acquired":false,"shares":23815,"price":29.3878,"value":699870.457,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.03 to $29.64, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":65373,"source":{"system":"sec-edgar","filing":"0001209191-19-043755","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1737287/000120919119043755/doc4.xml","form_type":"4"}},{"id":3452946,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":64703,"kind":"person","name":"MOORE ALISON","position":1,"cik":"0001754937","reported_name":"MOORE ALISON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2019-07-30T22:23:39.000Z","date":"2019-07-29","kind":"exercise","acquired":true,"shares":23815,"price":2.27,"value":54060.05,"ownership":{"direct":true},"balance_after":89188,"source":{"system":"sec-edgar","filing":"0001209191-19-043755","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1737287/000120919119043755/doc4.xml","form_type":"4"}},{"id":3452945,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":64703,"kind":"person","name":"MOORE ALISON","position":1,"cik":"0001754937","reported_name":"MOORE ALISON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2019-07-30T22:23:39.000Z","date":"2019-07-26","kind":"sale","acquired":false,"shares":13193,"price":29.1817,"value":384994.1681,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.39, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":65373,"source":{"system":"sec-edgar","filing":"0001209191-19-043755","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1737287/000120919119043755/doc4.xml","form_type":"4"}},{"id":3452944,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":64703,"kind":"person","name":"MOORE ALISON","position":1,"cik":"0001754937","reported_name":"MOORE ALISON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2019-07-30T22:23:39.000Z","date":"2019-07-26","kind":"exercise","acquired":true,"shares":13193,"price":2.27,"value":29948.11,"ownership":{"direct":true},"balance_after":78566,"source":{"system":"sec-edgar","filing":"0001209191-19-043755","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1737287/000120919119043755/doc4.xml","form_type":"4"}},{"id":3474293,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":64703,"kind":"person","name":"MOORE ALISON","position":1,"cik":"0001754937","reported_name":"MOORE ALISON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Option to Purchase Common Stock (Right to Buy)","published_at":"2019-07-01T20:32:15.000Z","date":"2019-06-28","kind":"exercise","acquired":false,"shares":27816,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-fourth of the 892,500 shares subject to the stock option vested on June 1, 2019, and the remaining shares vest in 36 successive equal monthly installments thereafter."}],"balance_after":815856,"derivative":{"exercise_price":2.27,"expiration_date":"2028-06-25","underlying":"Common Stock","underlying_shares":27816},"source":{"system":"sec-edgar","filing":"0001209191-19-039728","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1737287/000120919119039728/doc4.xml","form_type":"4"}},{"id":3474292,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":64703,"kind":"person","name":"MOORE ALISON","position":1,"cik":"0001754937","reported_name":"MOORE ALISON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2019-07-01T20:32:15.000Z","date":"2019-06-28","kind":"exercise","acquired":true,"shares":27816,"price":2.27,"value":63142.32,"ownership":{"direct":true},"balance_after":65373,"source":{"system":"sec-edgar","filing":"0001209191-19-039728","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1737287/000120919119039728/doc4.xml","form_type":"4"}},{"id":3499875,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":64703,"kind":"person","name":"MOORE ALISON","position":1,"cik":"0001754937","reported_name":"MOORE ALISON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Option to Purchase Common Stock (Right to Buy)","published_at":"2019-06-05T21:49:52.000Z","date":"2019-06-03","kind":"exercise","acquired":false,"shares":48828,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"One-fourth of the 892,500 shares subject to the stock option vested on June 1, 2019, and the remaining shares vest in 36 successive equal monthly installments thereafter."}],"balance_after":843672,"derivative":{"exercise_price":2.27,"expiration_date":"2028-06-25","underlying":"Common Stock","underlying_shares":48828},"source":{"system":"sec-edgar","filing":"0001209191-19-034861","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1737287/000120919119034861/doc4.xml","form_type":"4"}},{"id":3499874,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":64703,"kind":"person","name":"MOORE ALISON","position":1,"cik":"0001754937","reported_name":"MOORE ALISON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2019-06-05T21:49:52.000Z","date":"2019-06-03","kind":"sale","acquired":false,"shares":1623,"price":27.3069,"value":44319.0987,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.30 to $27.31, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":37557,"source":{"system":"sec-edgar","filing":"0001209191-19-034861","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1737287/000120919119034861/doc4.xml","form_type":"4"}},{"id":3499873,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":64703,"kind":"person","name":"MOORE ALISON","position":1,"cik":"0001754937","reported_name":"MOORE ALISON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2019-06-05T21:49:52.000Z","date":"2019-06-03","kind":"sale","acquired":false,"shares":47205,"price":26.7441,"value":1262455.2405,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.30 to $27.29, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":39180,"source":{"system":"sec-edgar","filing":"0001209191-19-034861","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1737287/000120919119034861/doc4.xml","form_type":"4"}},{"id":3499872,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":64703,"kind":"person","name":"MOORE ALISON","position":1,"cik":"0001754937","reported_name":"MOORE ALISON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2019-06-05T21:49:52.000Z","date":"2019-06-03","kind":"exercise","acquired":true,"shares":48828,"price":2.27,"value":110839.56,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 507 shares of the Issuer's common stock acquired by the reporting person on March 15, 2019 pursuant to an employee stock purchase program."}],"balance_after":86385,"source":{"system":"sec-edgar","filing":"0001209191-19-034861","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1737287/000120919119034861/doc4.xml","form_type":"4"}},{"id":3592255,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":64703,"kind":"person","name":"MOORE ALISON","position":1,"cik":"0001754937","reported_name":"MOORE ALISON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2019-03-15T21:22:20.000Z","date":"2019-03-13","kind":"grant","acquired":true,"shares":83500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the stock option shall vest on the first anniversary of the grant date, and the remaining shares shall vest in 36 equal monthly installments thereafter."}],"balance_after":83500,"derivative":{"exercise_price":26.89,"expiration_date":"2029-03-12","underlying":"Common Stock","underlying_shares":83500},"source":{"system":"sec-edgar","filing":"0001209191-19-019767","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1737287/000120919119019767/doc4.xml","form_type":"4"}},{"id":3592254,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":64703,"kind":"person","name":"MOORE ALISON","position":1,"cik":"0001754937","reported_name":"MOORE ALISON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2019-03-15T21:22:20.000Z","date":"2019-03-13","kind":"grant","acquired":true,"shares":37050,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":37050,"source":{"system":"sec-edgar","filing":"0001209191-19-019767","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1737287/000120919119019767/doc4.xml","form_type":"4"}}]}